Bispecific antibodies
These companies develop engineered antibodies that bind two targets at once or steer T cells to diseased cells.
+35.9%
over 1 year · S&P 500 +11.6%
Key indicators
Health
51 / 100
Fragile
Solid
Price
P/E 27
Cheap
Expensive
Up over 1 year
8 of 13
Wallets over 90 days
1 / 3 buys / sells
Buys
Sells
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 15 companies
AMGN
+42.3%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
A
Amgen
AMGN
91.7%
+42.3%
S
Summit Therapeutics
SMMT
4.7%
−24.9%
X
Xencor
XNCR
1.0%
+157.7%
V
Vir Biotechnology
VIR
0.7%
+74.4%
Z
Zymeworks
ZYME
0.7%
+35.5%
C
Cullinan Therapeutics
CGEM
0.3%
+23.1%
A
Attovia Therapeutics
ATTO
0.3%
J
Janux Therapeutics
JANX
0.3%
−60.1%
B
Bicara Therapeutics
BCAX
0.2%
−32.8%
C
Crescent Biopharma
CBIO
0.2%
+8.4%
B
Bambusa Therapeutics
BBTX
B
BioNTech
BNTX
−23.4%
G
Genmab
GMAB
+68.6%
I
Immatics
IMTX
−40.1%
L
Lakefront Biotherapeutics
LKFT
+5.2%